Skip to content
Charles River Labs - ICH M12: How Will New Regulatory Harmonization Impact Drug Developers? episode artwork

Nov 3, 2024 32 min

Charles River Labs - ICH M12: How Will New Regulatory Harmonization Impact Drug Developers?

from The Big4Bio Podcast Hosted by Big4Bio

The recently released update to the International Council for Harmonisation M12 guidelines provides a consistent approach to drug-drug interaction studies across different regulatory agencies. The new guidelines replace regional and local ones and set a global standard for addressing drug-drug interactions. We spoke to Michael Templin, Senior Principal Scientific Advisor for Charles River Laboratories; and Marko Andric, Senior Business Development Director, Late Discovery, for Charles River Laboratories; about the new guidelines, changes drug developers will need to make in their approach to pre-clinical development, and the tools and technologies that might help them comply. A related webinar on the guidelines can be found at www2.criver.com/l/60962/2024-11-05/n5wj6y

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

Charles River Labs - ICH M12: How Will New Regulatory Harmonization Impact Drug Developers?

0:00 32:42

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of The Big4Bio Podcast?

This episode is 32 minutes long.

When was this The Big4Bio Podcast episode published?

This episode was published on November 3, 2024.

Can I download this The Big4Bio Podcast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.